Literature DB >> 31319973

Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.

Yariswamy Manjunath1, Sathisha V Upparahalli2, Kanve N Suvilesh2, Diego M Avella1, Eric T Kimchi1, Kevin F Staveley-O'Carroll1, Guangfu Li1, Jussuf T Kaifi3.   

Abstract

OBJECTIVES: Circulating tumor cell (CTC) clusters (≥2 CTCs in aggregate) detected in the peripheral blood have predictive value in solid cancers, including non-small cell lung cancer (NSCLC). The goal of the study was to investigate the presence of CTC clusters in NSCLC patients and in high-risk screening subjects having no or benign nodules in a screening low-dose CT (LDCT).
MATERIALS AND METHODS: In a prospective pilot trial, 7.5 ml peripheral blood was collected from treatment-naïve NSCLC patients, LDCT screening subjects (55-80 years, ≥30 pack-year smoking history) with no (Lung-RADS 1) or benign lung nodules (Lung-RADS 2), and healthy never-smoking controls. CTCs were enriched by size, also allowing CTC cluster isolation. For CTC identification and enumeration, immunofluorescence staining was performed for cytokeratins (CK) 8/18 and/or 19, EpCAM, CD45, and nuclei were stained with DAPI. Clinicopathological data were collected, and LDCT interpreted by the American College of Radiology Lung-RADS criteria.
RESULTS: CTC clusters were detected in 12/29 (41.4%) of all NSCLC patients, but not found in 31 high-risk screening subjects with Lung-RADS 1 or Lung-RADS 2 (P < 0.05). Since non-clustered, single CTCs were detectable in both groups of NSCLC patients (100%) and in 18/31 (58.1%) of high-risk screening subjects. No CTCs were detected in 20 healthy control subjects.
CONCLUSION: This pilot study suggests that CTC clusters are a useful and specific liquid biomarker to further explore for screening by LDCT and risk stratification of NSCLC patients. Future prospective studies with higher subject numbers will need to be performed.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Circulating tumor cells; Liquid biomarkers; Lung cancer screening; Non-small cell lung cancer

Mesh:

Substances:

Year:  2019        PMID: 31319973     DOI: 10.1016/j.lungcan.2019.06.016

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

1.  Vein-first Lobectomy for Lung Cancer Assessed According to the Status of Clustered Circulating Tumour Cells.

Authors:  Noriyoshi Sawabata; Shigeru Nakane; Daiki Yoshikawa; Takashi Watanabe; Takeshi Kawaguchi; Noriko Ouji-Sageshima; Keiji Kushibe; Toshihiro Ito
Journal:  Cancer Diagn Progn       Date:  2021-11-03

2.  Circulating Tumor-Macrophage Fusion Cells and Circulating Tumor Cells Complement Non-Small-Cell Lung Cancer Screening in Patients With Suspicious Lung-RADS 4 Nodules.

Authors:  Yariswamy Manjunath; Kanve Nagaraj Suvilesh; Jonathan B Mitchem; Diego M Avella Patino; Eric T Kimchi; Kevin F Staveley-O'Carroll; Klaus Pantel; Huang Yi; Guangfu Li; Peter K Harris; Aadel A Chaudhuri; Jussuf T Kaifi
Journal:  JCO Precis Oncol       Date:  2022-03

3.  18F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer.

Authors:  Diego M Avella; Yariswamy Manjunath; Amolak Singh; Chelsea B Deroche; Eric T Kimchi; Kevin F Staveley-O'Carroll; Jonathan B Mitchem; Eric Kwon; Guangfu Li; Jussuf T Kaifi
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 4.  Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors:  Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal:  Biomedicines       Date:  2022-05-20

Review 5.  Possible role of circulating tumor cells in early detection of lung cancer.

Authors:  Cristina Poggiana; Elisabetta Rossi; Rita Zamarchi
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 3.005

6.  Efficient isolation and quantification of circulating tumor cells in non-small cell lung cancer patients using peptide-functionalized magnetic nanoparticles.

Authors:  Naixin Liang; Lei Liu; Ping Li; Yuan Xu; Yingshuo Hou; Jiaxi Peng; Yang Song; Zhongxing Bing; Yadong Wang; Yanyu Wang; Ziqi Jia; Xiaoying Yang; Da Li; Huihui Xu; Qian Yu; Shanqing Li; Zhiyuan Hu; Yanlian Yang
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

7.  Role of circulating tumor cells in diagnosis of lung cancer: a systematic review and meta-analysis.

Authors:  Qingtao Zhao; Zheng Yuan; Huien Wang; Hua Zhang; Guochen Duan; Xiaopeng Zhang
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

8.  The combination of computed tomography features and circulating tumor cells increases the surgical prediction of visceral pleural invasion in clinical T1N0M0 lung adenocarcinoma.

Authors:  Jinghan Shi; Fei Li; Fujun Yang; Zhengwei Dong; Yan Jiang; Dania Nachira; Justyna Chalubinska-Fendler; Terence T Sio; Yo Kawaguchi; Hiromitsu Takizawa; Xiao Song; Yang Hu; Liang Duan
Journal:  Transl Lung Cancer Res       Date:  2021-11

Review 9.  Collective metastasis: coordinating the multicellular voyage.

Authors:  Emma Wrenn; Yin Huang; Kevin Cheung
Journal:  Clin Exp Metastasis       Date:  2021-07-12       Impact factor: 4.510

Review 10.  Circulating Tumor Cell Clusters: United We Stand Divided We Fall.

Authors:  Samuel Amintas; Aurélie Bedel; François Moreau-Gaudry; Julian Boutin; Louis Buscail; Jean-Philippe Merlio; Véronique Vendrely; Sandrine Dabernat; Etienne Buscail
Journal:  Int J Mol Sci       Date:  2020-04-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.